DS
IOVA icon

DRW Securities’s Iovance Biotherapeutics IOVA Stock Holding History

DRW Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.5K Sell
10,935
-40,628
-79% -$154K ﹤0.01% 898
2026
Q1 		$181K Buy
51,563
+23,005
+81% +$73.6K ﹤0.01% 1137
2025
Q4 		$78K Buy
+28,558
New +$66.1K ﹤0.01% 1089
2025
Q3 		– Sell
-38,033
Closed -$65.4K – 1459
2025
Q2 		$65.4K Buy
+38,033
New +$94.6K ﹤0.01% 1032
2024
Q4 		– Sell
-12,854
Closed -$121K – 691
2024
Q3 		$121K Buy
+12,854
New +$122K ﹤0.01% 531
2018
Q2 		– Sell
-18,000
Closed -$304K – 139
2018
Q1 		$304K Buy
+18,000
New +$273K 0.02% 98

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

DRW Securities's IOVA Position: Q2 2026 in Review

DRW Securities reduced its Iovance Biotherapeutics (IOVA) stake by 79% in Q2 2026, selling an estimated $154K and leaving 10,935 shares worth $45.5K. The position accounts for ﹤0.01% of the portfolio, ranked #898.

DRW Securities first reported a position in IOVA in Q1 2018 and has held it in 6 quarters since. The position peaked at $304K in Q1 2018. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • DRW Securities held 10,935 shares of Iovance Biotherapeutics worth $45.5K as of Q2 2026.
  • DRW Securities sold 40,628 Iovance Biotherapeutics shares in Q2 2026, an estimated $154K.
  • Iovance Biotherapeutics made up ﹤0.01% of DRW Securities's portfolio in Q2 2026, its #898 holding.
  • DRW Securities first reported a position in Iovance Biotherapeutics in Q1 2018 and has held it in 6 quarters since.
  • DRW Securities's Iovance Biotherapeutics position peaked at $304K in Q1 2018.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.